Veranda Health Announces New Funding Round by Johnson & Johnson

Veranda Health, a company that uses a real-world data (RWD) network to produce drug lifecycle and medical practice insights, has announced new funding from Johnson and Johnson. The deal, which amounts to $150 million, will be used to further develop their life science data services to deliver better value to providers taking advantage of their RWD.

According to This Week in Digital, “Verana Health is poised to accelerate its position as a market leader in powering quality real-world data to drive quality insights across the drug lifecycle with this infusion of capital. The three-year-old company will build upon its strong technology and data ecosystem—the VeraQ™ platform and its curated Qdata™ in ophthalmology, neurology, and urology—to advance clinical trials enablement, software-as-a-service, and real-world evidence. The Company will also expand upon its established artificial intelligence (AI) capabilities with a particular focus on its pioneering use of natural language processing (NLP) to extract insights from unstructured text data in electronic health record (EHR) notes.”

Read the entire press release by clicking here.

(Source: This Week in Digital, January 15^th, 2022)